Compare AngloGold Ashanti Limited (AU) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Mesoblast Limited — how do they compare? AngloGold Ashanti Limited trades at $99.01 (market cap $49.19B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: AngloGold Ashanti Limited is far larger — about 22.8× Mesoblast Limited's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| AU | MESO | |
|---|---|---|
Market Cap | $49.19B | $2.16B |
Sector | Basic Materials | Technology |
52-Week High | $128.26 | $20.96 |
52-Week Low | $52.15 | $12.88 |
Enterprise Value | $48.20B | $2.17B |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) surged 9.85% to $96.22 on strong gold price momentum and positive Q2 earnings. The stock trades near its 52-week high with bullish technical indicators and robust fundamentals including 26.64% net margins and 46.5% ROE. Recent quarterly results showed mixed performance with Q1 beating expectations while Q2 slightly missed, but strong free cash flow growth supports increased shareholder returns including dividends and a $2 billion buyback program.
Outlook remains positive with analyst consensus at $120.33 target (25% upside) and 64% buy ratings. Key catalysts include H2 production growth and gold price strength, while risks involve operational disruptions and commodity volatility. The company's improving balance sheet and cash generation support continued dividend payments and strategic initiatives.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
